{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:11:45Z","timestamp":1761919905424,"version":"3.40.5"},"reference-count":18,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:p>Vanishing bile duct syndrome (VBDS) is a rare disorder characterized by loss of interlobular bile ducts and progressive worsening cholestasis. The acute presentation of this disease is typically associated with a drug hypersensitivity and Stevens-Johnson syndrome\/toxic epidermal necrolysis (TEN). The mainstay of treatment has been ursodeoxycholic acid with mixed results from immunosuppressive regimens. Anti\u2013tumor necrosis factor-\u03b1 and plasmapheresis have been speculated to be of potential benefit. It is hoped that early identification and intervention in VBDS secondary to Stevens-Johnson syndrome\/TEN with continued reporting will lead to better regimens and outcomes. Our case report details the first reported use of infliximab and plasmapheresis, in addition to steroids, in a patient with VBDS secondary to TEN, as well as a literature review that supports a mechanism for why these modalities could be effective treatments. Unfortunately, our patient died, and the use of these therapies had an unclear benefit on his liver and skin disease. We hope that additional work can be published to confirm or refute their utility in the treatment of these diseases.<\/jats:p>","DOI":"10.1542\/peds.2013-2239","type":"journal-article","created":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T04:29:08Z","timestamp":1411446548000},"page":"e1194-e1198","source":"Crossref","is-referenced-by-count":21,"title":["Infliximab\/Plasmapheresis in Vanishing Bile Duct Syndrome Secondary to Toxic Epidermal Necrolysis"],"prefix":"10.1542","volume":"134","author":[{"given":"Jason C.","family":"White","sequence":"first","affiliation":[{"name":"Pediatric Residency Program, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Appleman","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, Department of Pediatrics, St Christopher\u2019s Hospital for Children, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"issue":"3","key":"2021120903440968400_B1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0016-5085(98)70154-4","article-title":"Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.","volume":"115","author":"Srivastava","year":"1998","journal-title":"Gastroenterology"},{"issue":"1","key":"2021120903440968400_B2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","article-title":"Vanishing bile duct syndrome.","volume":"12","author":"Reau","year":"2008","journal-title":"Clin Liver Dis"},{"issue":"1","key":"2021120903440968400_B3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1013296310944","article-title":"Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes.","volume":"47","author":"Garcia","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"29","key":"2021120903440968400_B4","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.3748\/wjg.14.4697","article-title":"Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.","volume":"14","author":"Okan","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"5","key":"2021120903440968400_B5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00004836-199010000-00014","article-title":"Small bile duct abnormalities in sarcoidosis.","volume":"12","author":"Murphy","year":"1990","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"2021120903440968400_B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002281-200001000-00012","article-title":"New pathogenetic insights into the sarcoid granuloma.","volume":"12","author":"Agostini","year":"2000","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"2021120903440968400_B7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpeds.2004.05.027","article-title":"Acute vanishing bile duct syndrome after ibuprofen therapy in a child.","volume":"145","author":"Taghian","year":"2004","journal-title":"J Pediatr"},{"issue":"3","key":"2021120903440968400_B8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.transproceed.2013.02.012","article-title":"ABO-incompatible liver transplantation in acute liver failure: a single Portuguese center study.","volume":"45","author":"Mendes","year":"2013","journal-title":"Transplant Proc"},{"issue":"2","key":"2021120903440968400_B9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1665-2681(19)32029-0","article-title":"Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms.","volume":"5","author":"Karnsakul","year":"2006","journal-title":"Ann Hepatol"},{"issue":"4","key":"2021120903440968400_B10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"issue":"4","key":"2021120903440968400_B11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment.","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2021120903440968400_B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/21548331.1990.11703976","article-title":"Disappearing bile ducts: immunologic mechanisms.","volume":"25","author":"Vierling","year":"1990","journal-title":"Hosp Pract (Off Ed)"},{"issue":"2","key":"2021120903440968400_B13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1089-3261(03)00032-1","article-title":"Drug-induced cholestasis.","volume":"7","author":"Levy","year":"2003","journal-title":"Clin Liver Dis"},{"issue":"3","key":"2021120903440968400_B14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14740338.2.3.287","article-title":"Drug-induced cholestasis.","volume":"2","author":"Velayudham","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"2021120903440968400_B15","unstructured":"Remicade [package insert]. Janssen Biotech, Inc., Horsham, PA; November 2013. Available at: http:\/\/www.remicade.com\/shared\/product\/remicade\/prescribing-information.pdf. Accessed December 14, 2013"},{"issue":"5","key":"2021120903440968400_B16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1744-9987.2008.00609.x","article-title":"Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan.","volume":"12","author":"Yamada","year":"2008","journal-title":"Ther Apher Dial"},{"issue":"4","key":"2021120903440968400_B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jca.21213","article-title":"Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases.","volume":"27","author":"Ko\u0161t\u00e1l","year":"2012","journal-title":"J Clin Apher"},{"issue":"6","key":"2021120903440968400_B18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.1840200610","article-title":"Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis.","volume":"20","author":"Moradpour","year":"1994","journal-title":"Hepatology"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e1194\/1099347\/peds_2013-2239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/134\/4\/e1194\/1099347\/peds_2013-2239.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T19:24:53Z","timestamp":1639077893000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/134\/4\/e1194\/32955\/Infliximab-Plasmapheresis-in-Vanishing-Bile-Duct"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,1]]},"published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2013-2239","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}